SEER Inquiry System - Report
Produced: 11/28/2024 5:28 PM
Question 20120016
Inquiry Details
References:
Heme & Lymph Manual & DB,Appendix F
Question:
Reportability--Heme & Lymphoid Neoplasms: Is "amyloidosis" reportable if the medical oncologist states that it is a malignancy? See Discussion.
Discussion:
Amyloidosis is not reportable per the Commission on Cancer guidelines. However, the medical oncologist at this facility states that it is a malignancy. The oncologist presented a case at Cancer Conference and indicated the patient has Stage III disease. Should this case be accessioned?
Answer:
For cases diagnosed 2010 and forward, access the Hematopoietic Database at http://seer.cancer.gov/seertools/hemelymph.
Amyloidosis, NOS is not reportable. It is listed in Appendix F of the Heme Manual on the Non-Reportable List for Hematopoietic Diseases.
Amyloidosis (AL) is term that refers to a group of conditions that include benign conditions (e.g., found in the pancreas of type II diabetes patients and in the brain lesions of Alzheimer patients) as well as in malignant diseases (e.g., AL found in multiple myeloma and ACal (calcitonin) found in medullary carcinoma of the thyroid). Amyliodosis, NOS is not a term that equates to a malignant diagnosis.
Check the medical record to see if this disease process is designated as either AL or ACal. There should be a malignant diagnosis such as multiple myeloma or medullary carcinoma of the thyroid in such cases rather than simply a diagnosis of amyloidosis. The malignancy needs to be coded, not the symptoms of the disease process.
SEER*Educate provides training on how to use the Heme Manual and DB. If you are unsure how to arrive at the answer in this SINQ question, refer to SEER*Educate to practice coding hematopoietic and lymphoid neoplasms. Review the step-by-step instructions provided for each case scenario to learn how to use the application and manual to arrive at the answer provided. https://educate.fhcrc.org/LandingPage.aspx.